ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 151 filers reported holding ARGENX SE in Q4 2019. The put-call ratio across all filers is 0.59 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,720,160 | +88.4% | 4,000 | +66.7% | 1.45% | +181.9% |
Q4 2023 | $913,032 | -81.4% | 2,400 | -80.9% | 0.51% | -84.5% |
Q2 2023 | $4,898,127 | +37.0% | 12,568 | +31.0% | 3.32% | +26.0% |
Q1 2023 | $3,574,533 | +85.0% | 9,594 | +88.1% | 2.63% | +121.4% |
Q4 2022 | $1,932,033 | -24.6% | 5,100 | -77.3% | 1.19% | -35.8% |
Q3 2019 | $2,564,000 | -77.6% | 22,500 | -72.2% | 1.85% | -54.6% |
Q2 2019 | $11,468,000 | +44.7% | 81,000 | +27.6% | 4.08% | +8.2% |
Q1 2019 | $7,927,000 | +55.7% | 63,500 | +19.8% | 3.77% | -3.0% |
Q4 2018 | $5,092,000 | -36.1% | 53,000 | -49.5% | 3.88% | +36.8% |
Q3 2018 | $7,963,000 | -78.8% | 105,000 | -76.8% | 2.84% | -57.5% |
Q2 2018 | $37,555,000 | +15.6% | 453,233 | +12.2% | 6.68% | +26.0% |
Q1 2018 | $32,483,000 | +59.3% | 403,821 | +25.0% | 5.30% | +37.8% |
Q4 2017 | $20,394,000 | +317.1% | 323,000 | +49.4% | 3.85% | +339.5% |
Q3 2017 | $4,890,000 | +50.8% | 216,255 | +41.5% | 0.88% | -3.4% |
Q2 2017 | $3,242,000 | – | 152,837 | – | 0.91% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Darwin Global Management, Ltd. | 285,198 | $106,259,071 | 29.06% |
Avoro Capital Advisors LLC | 1,287,500 | $479,696,750 | 7.11% |
Paradigm Biocapital Advisors LP | 181,172 | $67,501,064 | 6.40% |
DCF Advisers, LLC | 25,700 | $9,575,310 | 5.86% |
Artia Global Partners LP | 36,404 | $13,563,402 | 5.01% |
Bellevue Group AG | 886,928 | $330,451,634 | 4.80% |
Fairmount Funds Management LLC | 73,526 | $27,394,317 | 4.71% |
Eagle Health Investments LP | 64,400 | $23,994,152 | 4.67% |
Decheng Capital Management III (Cayman), LLC | 27,429 | $10,219,497 | 4.12% |
RTW INVESTMENTS, LP | 482,195 | $179,656,213 | 3.74% |